NHS Cancer Programme Innovation Open Call Applicant Guidance

Please provide the title for the project. This should be descriptive, concise and contain keywords relevant to the project. Any abbreviations should be spelled out in full.

Please name the organisation that will be responsible if the project is funded, including management of the funding, project deliverables and arising intellectual properties.

Projects can be up to 24 months in duration.

This will be auto populated based on the information provided in Section 6.

The upper funding limit of the NHS Cancer Programme Innovation Open Call 3 is £4 million excluding VAT.

Please choose the most appropriate description of the innovation using the dropdown list provided. If “Other” is selected, please provide a short description of the innovation (max 20 words).

Please choose the most appropriate categories using the list provided.

Please indicate the main tumour type targeted by the proposed innovation (e.g., non-small cell lung cancer, lung adenoma, etc.).

Please choose the most appropriate TRL of the innovation using the dropdown list provided.

Please choose the most appropriate health category related to your application using the dropdown list provided.

Please select all that apply from the list provided.

Please describe the role of the Health Innovation Network in the project (max 100 words).

Please select all that apply from the list provided.

Please describe the role of Cancer Alliance(s) in the project and the level of engagement to date (max 100 words).

Please provide a narrative description for what the innovation is and how it addresses the competition challenge.

The following should be provided:

• A brief description of the proposed solution

• What is the problem that the solution aims to address and how does this meet the published Challenge Brief?

• What are the expected outcomes of the project?

• How will the solution benefit patients, the NHS and/or Social Care sector and the wider market?

Please describe how the proposed innovation will improve early diagnosis. This section is supported by the “Early Diagnosis Impact Assessment” Excel template, which can be found on the competition webpage. You must complete this template and upload it to Section 7 “Supporting Information”. Please use this section to support the data provided in your template and to explain how your solution will increase the proportion of cancers diagnosed at stages one and two. Please ensure you reference the relevant options below in your answer:

• Increasing cancer detection in asymptomatic population
• Improving screening uptake/adherence
• Proactively target/stratify patients
• Encourage patients to present earlier
• Increasing referrals
• Rule out/in for lower risk patients

The applicants should address the following questions in detail:

What stage of development is your innovation? In particular, the following evidence should be provided:

• UKCA certification for the innovation in the proposed pathway. Please provide proof of certification in Section 7.

• If CE marked but not yet UKCA certified, please provide a clear roadmap to achieve UKCA mark by June 2028 for general medical devices or June 2030 for in vitro diagnostic medical devices.

• If CE mark or UKCA are not relevant, please specify if other regulatory approval is needed and whether this has been obtained.

• If UKCA/CE marks have not been achieved, but other equivalent regulatory approvals are available in different countries (e.g., FDA), please provide evidence and detailed plans for regulatory approvals in the UK as part of the project.

• Digital interventions must consult the NICE Digital Health Technology Framework and the application should evidence plans to meet the appropriate evidence guidelines. This comprises both clinical effectiveness and economic evaluation. Please consult the NHS England guidelines for “Designing and building products and services” for the latest links to relevant standards, guidelines and consultations.

• Evidence that NHS Digital Technology Assessment Criteria (DTAC) has been considered, if relevant.

• Demonstration and evidence of safety and clinical efficacy through the appropriate studies, e.g., clinical trials.

What is the evidence?

Please provide a brief narrative explaining the evidence base and what has been done so far to demonstrate that your solution can improve earlier diagnosis, ideally evidencing a reduction in stage of diagnosis to stages one or two.

• This may include a description of the sample size, which may include the number of patients and sites involved in the generation of evidence.

• Where relevant, a clear description of the evidence for clinical, system and administrative benefits should be described. These may include sensitivity, specificity, QALYs, physical and mental health outcomes, system/administrative efficiency, patient attendance, etc.

• Whether Patient and public involvement and engagement (PPIE) played a role in the development of the innovation and how PPIE contributed to the studies to gather evidence.

Please provide a list of references cited throughout the application including the list of evidence on safety and efficacy (e.g., sensitivity, specificity, positive and negative predictive values (PPV and NPV respectively)) of the proposed solution (i.e., peer reviewed publications, conference proceedings, poster, reports, etc.) in Section 7 “Supporting Information”.

Could your innovation be used/deployed in different ways?

For example, at different points in the pathway for different target populations, for different uses/outcomes. If yes, please explain the different options available, then clearly show which option you are considering when completing this application. If re-deployed from a different cancer type/disease area/indication, evidence must be provided to support the new clinical pathway.

Where does your innovation fit within the care pathway?

• Please provide a pathway map showing the innovation disrupted pathway against the normal clinical pathway in Section 7 “Supporting Information”. Please aim to include all steps in the pathway (including triage/analysis etc.). Where possible, please include statistics or percentages of patients/referrals going down the different routes within the pathway.

• Describe how your innovation would improve the proposed care pathway (e.g., better patient outcomes, reduce hospital admissions, length of hospital stays, and late-stage treatment costs).

• Please provide data to evaluate feasibility and impact on Early Cancer detection and diagnosis in Section 7 “Supporting Information”. Early Diagnosis Impact Assessment” Excel template is available on the competition webpage.

What is the impact on cancer services and on the system?

Please provide any preliminary considerations on how the innovation would impact on cancer service and how the system will need to adapt (including people, processes and culture) in order to deliver system-wide benefits (e.g., output of NICE META tool, other).

The applicants are expected to provide the following information: 

• The proposed work packages, including PPIE, equity of access and net zero elements of the proposal. 

• Detail of what will be conducted within each of the work packages, the rationale behind these work packages, key measurable deliverables, and how these will be delivered.  

• For implementation studies, please provide a detailed description of the implementation process and how it will be measured. These may include staff and resources needed, consequences to the customer upon implementation, impacts across the wider health/social care system, and costs in resources and time to implement alongside the price.  

• Study design. This may include both quantitative and qualitative methodologies, power calculation, study cohort, the patient/service users affected and if relevant, implementation research plan in the context of where the innovation will be delivered.  

• A project Gantt chart to support the project breakdown must be provided in Section 7 “Supporting Information”. Note: The Gantt chart must:

• not exceed 1 single side of A4

• include steps needed to obtain relevant approvals, if applicable.

• Key risks to the project and state how these will be mitigated against. 

• If you are not planning to engage with patients, you MUST explain why. 

• Please note that from 1 April 2023, NHS organisations requires all suppliers of new contracts for goods, services, and / or works with an anticipated contract value above £5 million per year (excluding VAT) to publish a Carbon Reduction Plan (CRP) for their emissions from the sources included in scope 1 and 2 of the Greenhouse Gas (GHG) protocol and a defined subset of scope 3 emissions. In view of this please make sure that you include a work package to develop such plan by the end of the project, if you don’t already have one.

Prior to the submission of the application please check if your project will require an NHS Research Ethics Committee (REC) review or any other type of review such as Research, Innovation and Development Advisory Committees (RIDAC) support (see below for more information on RIDAC).

• Pre-empting and including relevant approvals in your project plan will prevent delays to your project. A drop-down list is provided to indicate whether any reviews and /or approvals are required either to deliver the implementation and/or any other part of the project plan. Please include more details in the text box provided if this is the case (max 200 words)  

• The RIDACs act as a support and advisory body within the 3 cancer screening programmes (breast, bowel & cervical) They help researchers and innovators with proposals for evaluation by assessing the potential impact of the proposed study to ensure participant benefit and safety, clinical service continuity, minimal service/workforce burden, that it is technically possible within the current IT systems and whether the data request is necessary, proportionate, and legal.

• The RIDAC team in the NHS England Vaccination and Screening Directorate is the point of contact and will help applicants through the required RIDAC application process. Applicants that are applying to the NHS Cancer Programme Innovation Open Call with a project that will impact breast, bowel or cervical screening programmes are asked to contact the NHS England Vaccination and Screening Directorate to understand if their project will benefit from going through the relevant RIDAC. If so, the NHS England Vaccination and Screening Directorate will be able to help refine the RIDAC proposal. Please email england.screening.research@nhs.net for more information.

Please describe your high-level evaluation plan in this section. All projects are required to conduct an independent (service) evaluation as part of the project. It is important that your evaluation is robust and can undergo independent scrutiny. The aim of the evaluation is to understand how your innovation is implemented, what impact it has, for whom, how, and why.  

All applicants are encouraged to read the following documents before completing this section:

• Evaluation Guidance for Applicants and Awardees

• An introductory guide to evaluation

• A Guide to Logic Models

If guidance on how commissioning an evaluation partner is needed, the applicants are encouraged to contact the SBRI Healthcare PMO to ask for further information.

Please consider the following elements when designing a real-world evaluation study:  

The unmet need assessed by relative priority nationally or regionally, including assessment of potential health gain. 

• The outcomes are strong enough to support scale and spread as expected. 

• The proposed method of implementation is easy, credible and adaptable for spread, including technical and operational elements. 

• Resources (finance/staff) are quantified and available across sufficient proportion of market. 

• There is appropriate economic assessment (e.g., return on investment).  

Please include the following detail in your real-world evaluation strategy: 

• Your evaluation questions. Make sure you include appropriate evaluation questions for the evaluation type.

• Your overarching evaluation aims (e.g., health economics, health outcomes, enablers and barriers to implementation and delivery). 

• The evaluation methods you propose to carry out (e.g., process, impact, economic).  

• Potential evaluation outcomes may include (this is not an exhaustive list):  

  • Clinical outcomes 
  • Time to and accuracy of diagnosis 
  • Outpatient appointments, including follow-up appointments 
  • Inpatient admissions, including bed-days, length of stay, and readmissions 
  • Ambulance calls 
  • Primary care appointments 
  • Medicines use 
  • Workforce capacity 
  • Releasing beds 
  • Quality of life 
  • Patient Experience 
  • Efficiencies 
  • Acceptability by patient and clinicians 
  • Costs, including procurement cost, associated costs, downstream cost, cost-saving, cost-releasing 
  • Sustainability and environmental impact 

• Your proposed evaluation partner, or if not known, an outline of the plan and a realistic cost estimation should be provided. Furthermore, please describe your approach for appointing an independent evaluation partner.  

• A logic model must be provided as an attachment in Section 7 “Supporting Information”.   The Logic model template is available on the competition webpage.

Please list up to 10 key milestones for the project along with timings for completion and appropriate success criteria.

The milestones should be comprehensive and the success criteria able to be assessed objectively (e.g., ‘all tests delivered to 99% accuracy’ or ‘for statistical significance, 2,000 samples must be processed’) with an emphasis throughout on practicality as this initiative is seeking evidence that the technology is viable in the proposed setting and can be effectively deployed to and adopted by NHS trusts. Appropriate record keeping and reporting are essential, but reports are not in themselves the main goal of the project.

Please indicate the roles that would contribute to the milestone under ‘Resource’. 

The delivery of the independent evaluation strategy and an evaluation report must be included as milestones.

Please provide details of any competitor innovations or market alternatives, which should include the following: 

• How is your proposed solution innovative

• The advantages of the proposed solution compared to the current standard of care and how it compares with it. 

• Details of any competing innovations or alternatives in the wider market (either on the market or in development) and describe the advantages and innovativeness of your proposed solution over these (i.e., what is your unique selling point).  

• Define the market you plan to address, including size, barriers to entry, and cost of the problem. 

• Companies may wish to consider working with other companies to bring forward solutions that can make a real difference.  

The definition of Intellectual Property (IP) includes patents, trademarks, designs, copyright (such as new software, checklists, scales, protocols, questionnaires, toolkits, guidelines or similar), research tools (such

as data analysis techniques, assays, cell lines, biomarkers, materials or equipment and devices) and (clinical) data.  

Please provide details on the following: 

• Any relevant existing background IP that will be utilised during the project and the current ownership arrangements, including patents or patent applications. 

• Any foreground IP which will be produced or improved during the project and how this IP will be captured and managed. Also provide details regarding expected ownership of foreground IP. 

• Any Freedom to Operate (FTO) search that has been conducted to date. If no search has been conducted, please explain your rationale. 

Please give an overview of your commercialisation and implementation strategies, and business plan for the product or service you are developing, including market launch and long-term adoption. Please include: 

• A review of the market size for proposed innovation in the UK, NHS and beyond (EU, US, etc) including growth rate of the market.  

• Expected penetration rate for the proposed innovation and barriers to market entry. 

• An overview of your commercialisation and business plans, with consideration of whom will use the solution, how it will be purchased and the likely cost of the solution.  

• Your business model for adoption, including implementation costs/implications, workforce requirements, etc. 

• If additional funding/investment is required to adopt the solution and what are your plans to raise the required capital.  

• If applicable, what are the plans for manufacturing the product and its current scale of production. How easy it is to scale up and if there are any issues that need to be resolved in order to institute a reliable manufacturing process. 

• Stakeholder engagement plan to support end user/operational/clinical uptake/buy-in/roll out of the innovation.

• The expected timescales for regional/national spread and the steps needed for adoption after the project. 

• Plans for long term sustainability of the technology. 

• How you will ensure that the innovation is affordable to the end users, NHS, and the wider system such as Integrated Care Systems (ICSs) both immediately and throughout the life of the product.  

• The evidence, both health economics and delivery of true impact, the NHS and wider system will require before the technology can be adopted. 

Patient and Public Involvement and Engagement (PPIE) is an accepted and recommended working practice within healthcare research ensuring that solutions are co-produced with patients, meet patient needs, and to ensure there is an acceptability among end-users. Applicants are expected to develop a thorough PPIE strategy as part of their project. Please consider including the following information in this section: 

• What are your plans for PPIE? Please provide specific details such as the way you will be involving and engaging with the patients and the public, the frequency at which you will plan activities and the specific outputs. 

• How will the relevant patient groups be involved in the development of innovation roll out and NHS adoption strategy? 

• How will you ensure that the innovation will be acceptable to patients, their families, carers, the wider support network, and healthcare professionals?

For further information regarding PPIE, we strongly recommend applicants to refer to the NIHR Guidance.

The SBRI Healthcare Programme is committed to promoting equality, diversity and inclusion, and reduce health inequalities through the development of technologies and solutions it is funding. Please provide the following detail in this section: 

• Whether the innovation might exacerbate health inequalities, which group(s) of the public/patients might be affected and how might you minimise this.  

• How the proposed innovation will ensure equity of access (e.g., underserved ethnicities, under-represented groups, economic groups, vulnerable groups, geography, digital exclusion, etc.) along with the steps to understand and alleviate potential negative impacts. More information on what constitutes health inequality can be found on The King’s Fund website.  

• Given the rural nature of many places, an over-reliance on home and community interventions needing to be permanently online should be considered (Wi-Fi and phone signals in rural locations may be weak or unreliable).  

• The cost of data use, which would negatively impact on accessibility by some low income or marginalised communities. 

• Please explain your assessment of local healthcare inequalities relative to the selected theme and the challenges facing your population, including which data sources have been used for informing this assessment and articulate the plans and objectives that are in place to deliver improvement against these challenges.  

Please describe the environmental impact that your solution will have on the NHS:

• Describe the environmental impact that your innovation may have in the care pathway/or care delivery it is intending to operate in.

• Detail how the innovation may contribute to reducing the NHS emissions (as explained in the Delivering a net zero NHS report, pages 11 and 12) and outline the quantified projected carbon savings including the methodology you used to estimate them. If you do not have any estimate, please articulate the methodology that you will adopt to quantify carbon emissions’ reductions and consider including a work package on this as part of the project.

• At an organisation level, please provide an outline on how you intend to fulfil the NHS Sustainable Supplier Roadmap, your organisation carbon reduction targets and the timelines to fully achieve the requirements set by the NHS Supplier Roadmap.

Please note, only named individuals included in the team, sub-contractor and advisor, or clinical/ healthcare professional (HCP) partner sections will be allowed to join the Interview Panel. Those named in Other Posts will not be able to join the Interview Panel.

Please note that members of the project team and project partners will need to be ‘invited’ through the Research Management System (RMS) portal via email to participate as team members, after which they must confirm their participation. The same process applies with the clinical partners and sub-contractors.

The application cannot be submitted without doing so.

Firstly, please ensure the team member(s), sub-contractor(s) and clinical partner(s) are registered onto the RMS portal (pmo.ccgranttracker.com). Once their account is registered and approved, the lead applicant will be able to search and ‘invite’ the team member(s), sub-contractor(s) and clinical partner(s) to the application.

Please ensure that those invited to collaborate on this application confirm their involvement in good time, as the application cannot be submitted without this.

The role and time commitment of team members, advisors and sub-contractors should be included.

Please note that for applications to be considered all fields within this section must be completed fully and to a satisfactory level. This includes complete descriptions of team members, sub-contractors, advisors, clinical/HCP partners, their experience, their roles in the project, Full Time Equivalent (FTE) commitments (if applicable) and costs.

Please add details of all team members and their role in the project. A maximum of 10 team members can be added. Do not include sub-contractors in this section.

Team members are those that belong to the host organisation and individuals with responsibility for the day-to-day management and delivery of the project. Team members are considered part of the project team and are expected to share responsibility for its successful delivery. Those outside of the host organisation should be listed as subcontractors or advisors.

Please provide a job title, detailed description of the role performed in the project, time allocated to the project and relevant experience and skills. Time allocated to the project should ideally be expressed as FTE percentage (the time allocated during the period of the project indicated as a proportion of the working hours for a Full Time Equivalent position).

Relevant commercial and management expertise of team members should be included.

Subcontractors and advisors are individuals that do not belong to the lead organisation and will provide a fee for service (or in-kind contribution); clinical partners should be listed in clinical/HCP partners section.

Please provide the details of any sub-contractors or advisors involved in your application. A maximum of 10 sub-contractors/advisors can be added. Please provide a job title, detailed description of the role performed in the project, time allocated to the project and relevant experience and skills of the sub-contractor(s) or advisor(s).

The use of sub-contractors is optional; however, where your proposal involves sub-contracted individuals or companies, or benefits from the input of named expert advisors, details should be provided.

While quotes for activities can be in the form of forecasts in this application, you will be asked to provide formal quotes as part of the due diligence process if you are successful. If an advisor provides services at no cost or at a level of expenses incurred only, this detail should be indicated.

Clinical/HCP partners are individuals that do not belong to the host organisation and will provide a fee for service (or ‘in kind’ contribution) in relation to the clinical elements of the project.

Please provide the organisation name, clinician/HCP’s job title, a detailed description of the role performed in the project, time allocated to the project and relevant experience and skills of the clinical/HCP partner(s).

The use of a clinical/HCP partner is not mandatory, but it is strongly recommended. A maximum of 10 clinical/HCP partners can be added.

Please provide a detailed description of any other posts that are yet to be confirmed or appointed for the project.

Please also provide the job title, a detailed description of the role performed in the project, time allocated to the project and relevant experience and skills that are required for the role. Those named in “Other Posts” will not be able to join the Interview Panel.

Please note that SBRI Healthcare is not a grant and not VAT exempt. If you are successful, you will be awarded an NHS Cancer Programme Development Agreement, which is subject to VAT. All project costs should be indicated as NET cost incurred and a VAT charge at 20% may be applied. Please note the maximum cost a proposed project can request is detailed in the Competition Brief and the associated Invitation to Tender available on the competition webpage.

Please provide a line-by-line summary of costs of the project in the table supplemented. The costs quoted must reflect actual costs at a “fair market value” and profit should not be included.

Please note, costs to support basic research, development of research hypotheses, and experimental designs that have no practical commercial application are not eligible.

Please note that when indicating costs, the NET costs should be provided in the respective rows of the table supplemented. Please see some general guidance here.

• Labour costs for all those contributing to the project
• Material costs (including consumables specific to the project)
• Capital equipment costs
• Sub-contract costs (including independent evaluation costs)
• Travel and subsistence costs
• Indirect costs
• Other costs
• Total NET costs (auto populated)
• Please confirm if you will be claiming VTA at 20% (please tick “YES” if you will apply VAT)
  *Please note VAT is the responsibility of the invoicing organisation.

Please provide a justification of the costs for the staff involved and quotes from sub-contractors where applicable.

If there is significant use of sub-contractors, please explain how these will be used and the costs of each. Please note the Assessors are required to judge the application finances in terms of value for money, evaluating whether the proposed cost for effort and deliverables in a proposal reflect a fair market price. Applicants are strongly encouraged to consider the guidance provided in the Cost breakdown section below and summarise the elements in the application justification section.

Itemisation of costs and methods of calculation may be requested at a later date to support the application.

Cost breakdown

Please download, complete and finally attach the Finance spreadsheet with the details of all your costs following the different costs categories:

• Labour costs
• Material costs
• Capital equipment costs
• Sub-contract costs
• Travel and subsistence costs
• Indirect costs
• Other costs

Please, when you compile your budget, make sure that you also include within the appropriate category the following costs, if appropriate for your project:

• Cost to supply the innovation
• Training costs
• Clinical staff time to administer the innovation
• Management costs for hospital trusts to implement the innovation
• Independent evaluation costs including data collection and analysis, impact on care pathway, clinician and patient acceptability, health economics
• Technology adaptation work (e.g., minor adaptations for user acceptability, system integration, etc.)

Please note that for the application to be considered, a complete breakdown of the requested budget using the template provided is required. Budget provided in other formats will not be accepted. The funding requested in the spreadsheet must be aligned with the application form.

Please use the following guidance and consider the following when completing the Finance spreadsheet.

Labour costs

• In the Labour costs section, please provide details of posts and salaries of team members. This includes name, role, grade (put N/A if not relevant), annual salary and on-costs (cost incurred by the organisation to employ someone), %FTE dedicated to the project and the total number of months on the project (1 -24). Please ensure the figures entered are in line with those entered in the application form.

• Full economic cost (FEC) calculations are not relevant in this context. SBRI is a competitive procurement mechanism and tenders are submitted by a variety of organisations. Whatever calculations are used to arrive at the tender price, each application is assessed against bids from other organisations. Applicants should bear this in mind when calculating their tender price. Costs should reflect fair market value.

• Review salary costs and challenge salaries that seem too high in comparison to what is “market fair rate”.

• Please note that the following are often challenged:

• Excessive time commitment for specific salaried staff.

• High number of salaried staff for size of project.

• Too few staff contracted for size of project or no salaried staff at host organisation.

Materials

• Please provide details of the consumables required for the project and justify the costs wherever possible, particularly for larger consumables items.

• Please ensure that granularity is provided on material and consumables.

• If a license for an app/service is listed, it is expected that it is at costs and no profit is charged.

Capital equipment

• Capital expenditure should be clearly justified in relation to the project and the cost should take into account the duration of the project.

• Leasing equipment from a provider or borrowing from existing facilities is an option to consider.

• Any equipment over the value of £250 should be itemised. Anything under can be grouped.

• All equipment should be clearly justified at the bottom of the spreadsheet.

Sub-contract

• Outline the hourly/daily rate for each provider including consultancy, sub-contractors, IP and legal. Here we also expect to see payment for PPIE time (rates should be provided to justify the costs), PPIE travel fees, accommodation and subsistence where applicable, support costs if required and training.

• If successful, quotes from individual subcontractors will be requested prior to contracting.

Travel and subsistence

• Please include project-related travel costs using the most economic means possible. Please note that meals & accommodation are acceptable.

• Remember to add details to justify the costs (number of visits, travel required, subsistence associated to a specific meeting, etc.) and provide details of conferences and the number of people attending (if applicable).

Indirect costs

• Indirect costs may include estate costs (e.g., building and premises costs), services/utilities, rent or lease, insurance, etc.

• Other indirect costs may include other departmental costs (for example Finance & HR).

• Overhead costs should be charged in proportion to the amount of effort deployed on the project and should be calculated using own cost rates. Costs that are considered unreasonable could be rejected.

Other costs

• This may include all other cost items which do not fit elsewhere, such as any dissemination costs related to publication or dissemination of findings. Please note that services outside England are acceptable but should be clearly justified in the justification section.

• Please note that a SBRI Healthcare award is not a grant but is considered as a development contract responding to a tender, as such, Full Economic Costing (FEC) is not covered. If the Lead Organisation is a university, please refer to your finance/contracts office for guidance on tender applications.

• Finance spreadsheet. The template is available on the competition webpage (mandatory).

• Gantt chart for the project (must not exceed 1 single side of A4), including steps required to obtain relevant review(s) and/or approval(s), if applicable (mandatory).

• Relevant documentation to support regulatory approval/compliance claims made in the proposal (mandatory).

• List of Reference (mandatory).

• List of evidence on safety and efficacy (e.g., sensitivity, specificity, positive and negative predictive values) for the proposed solution (i.e., peer reviewed publications, conference proceedings, reports, etc.) (mandatory).

• A completed “Early diagnosis impact assessment”. The template is available on the competition webpage (mandatory).

• Pathway map showing the innovation disrupted pathway against the normal clinical pathway (must not exceed 1 single side of A4), including all steps in the pathway (including triage/analysis etc.) and statistics or percentages of patients/referrals going down the different routes within the pathway, if possible (mandatory).

• A completed logic model (2 single sides of A4). The logic model template is available on the competition webpage (mandatory).

• Additional supporting document (2 single sides of A4, optional).

Additional supporting documents may include a flow diagram illustrating the study design and the flow of participants, diagrams, pictures etc. If submitting a flow diagram, applicants should also describe complex interventions and controls as accurately and fully as possible within their diagram.

IMPORTANT: Uploads MUST be provided as a Word, Excel or PDF document or you may not be able to submit your application, or it may be difficult for the Panel to view the required information in order to assess your application.

Any documents exceeding the defined page limit will NOT be reviewed.